Back

Left atrial strain predicts adverse events in hypertrophic cardiomyopathy: preliminary results from a CMR study

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Characterisation of cardiomyopathies with cardiac magnetic resonance Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Francisco Gonzalez-Santorum

Hospital Vall Dhebron, Barcelona (Spain)

7 More presentations in this session

Presentation thumbnail
Imaging predictors of adverse prognosis in fabry disease cardiomyopathy: a systematic review and meta-analysis
Mr T. Rojanathagoon (University Of Nottingham, GB)
Abstract Slides Video
Presentation thumbnail
Comparative assessment of extracellular volume metrics in predicting adverse outcomes in patients with transthyretin amyloid cardiomyopathy
Doctor C. Kronberger (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Study design of the CARDIO-TTRansform cardiac magnetic resonance imaging substudy
Professor M. Fontana (London, GB)
Abstract Slides Video
Presentation thumbnail
Myocardial determinants of Functional limitation in advanced Fabry cardiomyopathy
Doctor G. Guida (San Donato Milanese, IT)
Abstract Slides Video
Presentation thumbnail
T2 mapping as a marker of active myocardial injury in Anderson-Fabry disease patients
Doctor M. Schiavo (Bologna, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Characterisation of cardiomyopathies with cardiac magnetic resonance

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Cardiac magnetic resonance-derived left atrial global longitudinal strain identifies low-risk patients with hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Association of left atrial strain with long-term cardiovascular mortality in hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Changes in CMR-derived global longitudinal strain, progression of fibrosis and outcome in hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources